Benign Prostatic Hyperplasia (BPH) Treatment Market Size, Share and Growth Outlook, 2026

Benign Prostatic Hyperplasia (BPH) Treatment Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Benign Prostatic Hyperplasia (BPH) Treatment Market size is forecast to increase from $14.53 Billion in 2026 to $22.13 Billion in 2034 at a CAGR of 5.4% between 2026 and 2034.

The Benign Prostatic Hyperplasia (BPH) Treatment market report provides detailed analysis and outlook of Benign Prostatic Hyperplasia (BPH) Treatment segments including By Treatment Type (Medication, Minimally Invasive Procedures, Invasive ), By Drug Class (Alpha-Blockers, 5-Alpha Reductase Inhibitors (5-ARIs), Phosphodiesterase-5 (PDE-5) Inhibitors, Combination Therapies), By Product (Resectoscopes, Urology Lasers, Prostatic Urethral Lift Systems, Water Vapor Ablation ), By End-User (Hospitals, Specialty Urology Clinics, Ambulatory Surgical Centers (ASCs)) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Benign Prostatic Hyperplasia (BPH) Treatment Industry Overview

Innovation Driving the Evolution of BPH Treatment Options

The benign prostatic hyperplasia (BPH) treatment industry is undergoing significant transformation as healthcare providers increasingly adopt minimally invasive therapies, robotic technologies, and targeted treatment approaches to improve patient outcomes. Growing prevalence of lower urinary tract symptoms among aging male populations is driving demand for alternatives to long-term medication use and conventional surgical procedures. Manufacturers and healthcare institutions are focusing on office-based interventions, tissue-preserving therapies, and advanced implant technologies that reduce recovery times while maintaining quality-of-life outcomes. The market is increasingly characterized by personalized treatment strategies designed to balance efficacy, safety, and preservation of sexual function.

Localized Drug Delivery Platforms Expanding Treatment Alternatives

One of the most notable developments in the BPH treatment industry is the emergence of localized therapeutic delivery technologies. At the American Urological Association Annual Meeting, Resurge Therapeutics presented positive clinical data from two studies evaluating its IntraProstatic Drug Elution (IPDE) platform. The technology utilizes bioabsorbable, paclitaxel-eluting implants that are placed directly within the prostate to provide localized and durable symptom relief. By delivering therapy directly to the target tissue, the platform aims to offer an office-based alternative to chronic oral medication regimens and more invasive surgical interventions. This approach reflects the growing industry focus on minimally invasive treatments that can provide sustained benefits while reducing systemic drug exposure.

Robotic Aquablation Advancing Precision Prostate Care

Robotic-assisted technologies are playing an increasingly important role in modern BPH management. Saint Peter’s University Hospital announced the integration of the HYDROS™ Robotic System for Aquablation therapy, an AI-powered treatment platform that utilizes a heat-free waterjet to remove excess prostate tissue. The technology is designed to deliver highly precise and personalized tissue resection while minimizing damage to surrounding anatomical structures. Recognition for superior clinical outcomes in outpatient prostate care highlights the growing adoption of robotic and image-guided treatment modalities that improve procedural consistency and patient recovery experiences. The combination of artificial intelligence and minimally invasive intervention is helping redefine standards in prostate tissue management.

Minimally Invasive Implants Supporting Functional Preservation

The industry is also witnessing increased adoption of implant-based therapies designed to preserve quality of life while alleviating urinary symptoms. Prodeon Medical received FDA 510(k) clearance for its Urocross Expander System, supported by clinical findings from the Expander-2 pivotal trial. The device provides a temporary minimally invasive implant option for managing lower urinary tract symptoms associated with BPH. A key advantage of the technology is its ability to preserve sexual function while maintaining flexibility for future treatment options if needed. Such developments demonstrate the growing emphasis on patient-centered therapies that address symptom relief without compromising long-term treatment choices or functional outcomes.

Benign Prostatic Hyperplasia (BPH) Treatment Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Benign Prostatic Hyperplasia (BPH) Treatment market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated (UroLift), ProArc Medical, Medtronic plc, Endo International plc, Lilly (Eli Lilly and Company), GlaxoSmithKline plc, Merck & Co., Inc., KARL STORZ SE & Co. KG. The Benign Prostatic Hyperplasia (BPH) Treatment market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Benign Prostatic Hyperplasia (BPH) Treatment industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Benign Prostatic Hyperplasia (BPH) Treatment Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Benign Prostatic Hyperplasia (BPH) Treatment companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Benign Prostatic Hyperplasia (BPH) Treatment markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Benign Prostatic Hyperplasia (BPH) Treatment Market Competitive Benchmarking and Company Analysis

Leading companies in Benign Prostatic Hyperplasia (BPH) Treatment industry include- Boston Scientific Corporation, Olympus Corporation, Teleflex Incorporated (UroLift), ProArc Medical, Medtronic plc, Endo International plc, Lilly (Eli Lilly and Company), GlaxoSmithKline plc, Merck & Co., Inc., KARL STORZ SE & Co. KG. The Benign Prostatic Hyperplasia (BPH) Treatment market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Benign Prostatic Hyperplasia (BPH) Treatment Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Benign Prostatic Hyperplasia (BPH) Treatment market remains one of the strongest-performing segments in the country.
The US Benign Prostatic Hyperplasia (BPH) Treatment Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Benign Prostatic Hyperplasia (BPH) Treatment market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Benign Prostatic Hyperplasia (BPH) Treatment industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Benign Prostatic Hyperplasia (BPH) Treatment markets

Canada's strong Benign Prostatic Hyperplasia (BPH) Treatment sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Benign Prostatic Hyperplasia (BPH) Treatment market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Benign Prostatic Hyperplasia (BPH) Treatment Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Benign Prostatic Hyperplasia (BPH) Treatment market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Benign Prostatic Hyperplasia (BPH) Treatment population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Benign Prostatic Hyperplasia (BPH) Treatment industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Benign Prostatic Hyperplasia (BPH) Treatment market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Benign Prostatic Hyperplasia (BPH) Treatment sales through 2034

France Benign Prostatic Hyperplasia (BPH) Treatment companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Benign Prostatic Hyperplasia (BPH) Treatment Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Benign Prostatic Hyperplasia (BPH) Treatment distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Benign Prostatic Hyperplasia (BPH) Treatment Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Benign Prostatic Hyperplasia (BPH) Treatment market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Benign Prostatic Hyperplasia (BPH) Treatment industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Benign Prostatic Hyperplasia (BPH) Treatment industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Benign Prostatic Hyperplasia (BPH) Treatment Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Benign Prostatic Hyperplasia (BPH) Treatment market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Benign Prostatic Hyperplasia (BPH) Treatment market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Benign Prostatic Hyperplasia (BPH) Treatment Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Benign Prostatic Hyperplasia (BPH) Treatment Market Segmentation

By Treatment Type
Medication
Minimally Invasive Procedures
Invasive
By Drug Class
Alpha-Blockers
5-Alpha Reductase Inhibitors (5-ARIs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Combination Therapies
By Product
Resectoscopes
Urology Lasers
Prostatic Urethral Lift Systems
Water Vapor Ablation
By End-User
Hospitals
Specialty Urology Clinics
Ambulatory Surgical Centers (ASCs)

Top Companies in Benign Prostatic Hyperplasia (BPH) Treatment Industry

Boston Scientific Corporation
Olympus Corporation
Teleflex Incorporated (UroLift)
ProArc Medical
Medtronic plc
Endo International plc
Lilly (Eli Lilly and Company)
GlaxoSmithKline plc
Merck & Co., Inc.
KARL STORZ SE & Co. KG

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025